Skip to main content
SpringerLink
Log in

Gut microbiota and obesity: implications for fecal microbiota transplantation therapy

  • Review
  • Published:
Hormones Aims and scope Submit manuscript

Abstract

Obesity is a major public health issue as it is causally associated with several chronic disorders, including type-2 diabetes, cerebrovascular disease (CVD), and cancer. In the United States and other countries worldwide, the obesity epidemic has drastically impacted the status of health of millions as well as healthcare costs. Aside from poor diet, hygiene, and genetics, there are many other factors thought to play an important role in the emergence of obesity. Nowadays, accumulating evidence is elucidating the relation of dysbiosis of intestinal bacteria with obesity and metabolic disorders. Certain gut microbial strains have been shown to inhibit or attenuate immune responses related to chronic inflammation in experimental models, suggesting that specific species among gut microbiota may play either a protective or a pathogenic role in the progression of obesity. Fecal microbiota transplantation (FMT) can therefore represent a therapeutic approach for obesity treatment. FMT is a relatively straightforward therapy that manipulates the human gastrointestinal (GI) microbiota by transferring healthy donor microbiota into an existing but disturbed microbial ecosystem. However, the relevant scientific work is still in its early stages. In this review, we summarize the cutting-edge research being done into FMT treatment of obesity, current issues in FMT treatment, and the future of FMT and microbial therapeutics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. James WPT, 2008 The epidemiology of obesity: the size of the problem. J Intern Med 263: 336–352.

    Article  PubMed  CAS  Google Scholar 

  2. Shulman GI, 2014 Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. NEJM 371: 2236–2237.

    Article  CAS  Google Scholar 

  3. Bouchard C, 2000 Inhibition of food intake by inhibitors of fatty acid synthase. NEJM 343: 1888–1889.

    Article  PubMed  CAS  Google Scholar 

  4. Kayser B, Verges S, 2013 Hypoxia, energy balance and obesity: from pathophysiological mechanisms to new treatment strategies. Obes Rev 14: 579–592.

    Article  PubMed  CAS  Google Scholar 

  5. Scarpellini E, Campanale M, Leone D, et al, 2012 Gut microbiota and obesity. Diges Dis 30: 196–200.

    Article  Google Scholar 

  6. Savage DC, 2003 Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol 31: 107–133.

    Article  Google Scholar 

  7. Ursell LK, Haiser HJ, Treuren WV, et al, 2014 The Intestinal Metabolome: An Intersection Between Microbiota and Host. Gastroenterology 146: 1470–1476.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Sender R, Fuchs S, Milo R, 2016 Are We Really Vastly Outnumbered? Revisiting the Ratio of Bacterial to Host Cells in Humans. Cell 164: 337–340.

    Article  PubMed  CAS  Google Scholar 

  9. Turnbaugh PJ, Ley RE, Hamady M, et al, 2007 The human microbiome project: exploring the microbial part of ourselves in a changing world. Nature 449: 804–810.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Zaneveld J, Turnbaugh PJ, Lozupone C, et al, 2008 Host-bacterial coevolution and the search for new drug targets. Curr Opin Chem Biol 12: 109–114.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Mackie RI, Sghir A, Gaskins HR, 1999 Developmental microbial ecology of the neonatal gastrointestinal tract. Am J Clin Nutr 69: 1035s–1045s.

    Article  PubMed  CAS  Google Scholar 

  12. Claesson MJ, Cusack S, O’Sullivan O, et al, 2011 Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci USA 108(Suppl 1): 4586–4591.

    Article  PubMed  Google Scholar 

  13. Zoetendal EG, Akkermans AD, De Vos WM, 1998 Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria. Appl Environ Microbiol 64: 3854–3859.

    PubMed  PubMed Central  CAS  Google Scholar 

  14. Koren O, Spor A, Felin J, et al, 2011 Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci USA 108(Suppl 1): 4592–4598.

    Article  PubMed  Google Scholar 

  15. Koren O, Goodrich JK, Cullender TC, et al, 2012 Host remodeling of the gut microbiome and metabolic changes during pregnancy. Cell 150: 470–480.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Abt MC, Artis D, 2009 The intestinal microbiota in health and disease: the influence of microbial products on immune cell homeostasis. Curr Opin Gastroen 25: 496–502.

    Article  CAS  Google Scholar 

  17. Tremaroli V, Bäckhed F, 2012 Functional interactions between the gut microbiota and host metabolism. Nature 489: 242–249.

    Article  PubMed  CAS  Google Scholar 

  18. Vinolo MAR, Rodrigues HG, Nachbar RT, et al, 2011 Regulation of Inflammation by Short Chain Fatty Acids. Nutrients 3: 858–876.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Zaibi MS, Stocker CJ, O’Dowd J, et al, 2010 Roles of GPR41 and GPR43 in leptin secretory responses of murine adipocytes to short chain fatty acids. FEBS Lett 584: 2381–2386.

    Article  PubMed  CAS  Google Scholar 

  20. Cox MA, Jackson J, Stanton M, et al, 2009 Short-chain fatty acids act as antiinflammatory mediators by regulating prostaglandin E and cytokines. World J Gastroentero 15: 5549–5557.

    Article  CAS  Google Scholar 

  21. Luster AD, Alon R, von Andrian UH, 2005 Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol 6: 1182–1190.

    Article  PubMed  CAS  Google Scholar 

  22. Aoyama M, Kotani J, Usami M, 2010 Butyrate and propionate induced activated or non-activated neutrophil apoptosis via HDAC inhibitor activity but without activating GPR-41/GPR-43 pathways. Nutrition 26: 653–661.

    Article  PubMed  CAS  Google Scholar 

  23. Ramos MG, Rabelo FL, Duarte T, et al, 2002 Butyrate induces apoptosis in murine macrophages via caspase-3, but independent of autocrine synthesis of tumor necrosis factor and nitric oxide. Braz J Med Biol Res 35: 161–173.

    Article  PubMed  CAS  Google Scholar 

  24. Kuritaochiai T, Ochiai K, Fukushima K, 2001 Butyric Acid-Induced T-Cell Apoptosis Is Mediated by Caspase-8 and -9 Activation in a Fas-Independent Manner. Clin Diagn Lab Immunol 8: 325–332.

    CAS  Google Scholar 

  25. Bailón E, Cueto-Sola M, Utrilla P, et al, 2010 Butyrate in vitro immune-modulatory effects might be mediated through a proliferation-related induction of apoptosis. Immunobiology 215: 863–873.

    Article  PubMed  CAS  Google Scholar 

  26. Chassaing B, Kumar M, Baker MT, et al, 2014 Mammalian gut immunity. Biomed J 37: 246–258.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Salminen S, Bouley C, Boutronruault MC, et al, 1998 Functional food science and gastrointestinal physiology and function. Brit J Nutr 80(Suppl 1): S147–S171.

    Article  PubMed  CAS  Google Scholar 

  28. Tsai F, Coyle WJ, 2009 The microbiome and obesity: is obesity linked to our gut flora? Curr Gastroen Rep 11: 307–313.

    Article  Google Scholar 

  29. Bäckhed F, Ding H, Wang T, et al, 2004 The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 101: 15718–15723.

    Article  PubMed  CAS  Google Scholar 

  30. Bäckhed F, Manchester JK, Semenkovich CF, et al, 2007 Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA 104: 979–984.

    Article  PubMed  CAS  Google Scholar 

  31. Turnbaugh PJ, Ley RE, Mahowald MA, et al, 2006 An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444: 1027–1031.

    Article  PubMed  Google Scholar 

  32. Ley RE, Backhed F, Turnbaugh P, et al, 2005 Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 102: 11070–11075.

    Article  PubMed  CAS  Google Scholar 

  33. Wellen KE, Hotamisligil GS, 2005 Inflammation, stress, and diabetes. J Clin Invest 115: 1111–1119.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Dibaise JK, Zhang H, Crowell MD, et al, 2008 Gut Microbiota and Its Possible Relationship With Obesity. Mayo Clin Proc 83: 460–469.

    Article  PubMed  Google Scholar 

  35. Cani PD, Amar J, Iglesias MA, et al, 2007 Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56: 1761–1772.

    Article  PubMed  CAS  Google Scholar 

  36. Pappo I, Becovier H, Berry EM, et al, 1991 Polymyxin B reduces cecal flora, TNF production and hepatic steatosis during total parenteral nutrition in the rat. J Surg Res 51: 106–112.

    Article  PubMed  CAS  Google Scholar 

  37. Ley RE, Turnbaugh PJ, Klein S, et al, 2007 Microbial ecology: Human gut microbes associated with obesity. Nature 444: 1022–1023.

    Article  CAS  Google Scholar 

  38. Turnbaugh PJ, Hamady M, Yatsunenko T, et al, 2009 A core gut microbiome in obese and lean twins. Nature 457: 480–484.

    Article  PubMed  CAS  Google Scholar 

  39. Walters WA, Xu Z, Knight R, 2014 Meta-analyses of human gut microbes associated with obesity and IBD. Febs Lett 588: 4223–4233.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. Kocełak P, Zakgołąb A, Zahorskamarkiewicz B, et al, 2013 Resting energy expenditure and gut microbiota in obese and normal weight subjects. Eur Rev Med Pharmacol Sci 17: 2816–2821.

    PubMed  Google Scholar 

  41. Faith JJ, Guruge JL, Charbonneau M, et al, 2013 The Long-Term Stability of the Human Gut Microbiota. Science 341: 1237439.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  42. Jumpertz R, Le DS, Turnbaugh PJ, et al, 2011 Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr 94: 58–65.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Cotillard A, Kennedy SP, Kong LC, et al, 2013 Dietary intervention impact on gut microbial gene richness. Nature 500: 585–588.

    Article  PubMed  CAS  Google Scholar 

  44. Le CE, Nielsen T, Qin J, et al, 2013 Richness of human gut microbiome correlates with metabolic markers. Nature 500: 541–546.

    Article  CAS  Google Scholar 

  45. Everard A, Beizer C, Geurts L, et al, 2013 Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA 110: 9066–9071.

    Article  PubMed  Google Scholar 

  46. Zhang H, Dibaise JK, Zuccolo A, et al, 2009 Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci USA 106: 2365–2370.

    Article  PubMed  Google Scholar 

  47. Kang Y, Zhang X, Cai Y, et al, 2016 Gut microbiota and metabolic disease: from pathogenesis to new therapeutic strategies. Rev Med Microbiol 27: 141–152.

    Article  Google Scholar 

  48. Fei N, Zhao L, 2013 An opportunistic pathogen isolated from the gut of an obese human causes obesity in germfree mice. Isme J 7: 880–884.

    Article  PubMed  CAS  Google Scholar 

  49. Cani PD, Amar J, Iglesias MA, et al, 2007 Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56: 1761–1772.

    Article  PubMed  CAS  Google Scholar 

  50. Sanders WE, Jr., Sanders CC, 1997 Enterobacter spp.: pathogens poised to flourish at the turn of the century. Clin Microbiol Rev 10: 220–241.

    PubMed  PubMed Central  Google Scholar 

  51. Bakken JS, Borody T, Brandt LJ, et al, 2011 Treating Clostridium difficile Infection With Fecal Microbiota Transplantation. Clin Gastroenterol H 9: 1044–1049.

    Article  Google Scholar 

  52. Smits LP, Bouter KEC, Vos WM, et al, 2013 Therapeutic potential of fecal microbiota transplantation. Gastroenterology 145: 946–953.

    Article  PubMed  Google Scholar 

  53. Gupta S, Allen-Vercoe E, Petrof EO, 2016 Fecal microbiota transplantation: in perspective. Therap Adv Gastroenterol 9: 229–239.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Borody TJ, Khoruts A, 2011 Fecal microbiota transplantation and emerging applications. Nat Rev Gastro Hepat 9: 88–96.

    Article  CAS  Google Scholar 

  55. Kang Y, Cai Y, 2017 Gut microbiota and hepatitis-B-virus-induced chronic liver disease: implications for faecal microbiota transplantation therapy. J Hosp Infect 96: 342–348.

    Article  PubMed  CAS  Google Scholar 

  56. Vrieze A, Nood EV, Holleman F, et al, 2012 Transfer of Intestinal Microbiota From Lean Donors Increases Insulin Sensitivity in Individuals With Metabolic Syndrome. Gastroenterology 143: 913–916 (e917).

    Article  PubMed  CAS  Google Scholar 

  57. Duncan S, Belenguer A, Holtrop G, et al, 2007 Reduced dietary intake of carbohydrates by obese subjects results in decreased concentrations of butyrate and butyrate-producing bacteria in feces. Appl Environ Microb 73: 1073–1078.

    Article  CAS  Google Scholar 

  58. Hamer HM, Jonkers D, Venema K, et al, 2008 Review article: the role of butyrate on colonic function. Aliment Pharm Therap 27: 104–119.

    Article  CAS  Google Scholar 

  59. Louis P, Flint HJ, 2009 Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. Fems Microbiol Lett 294: 1–8.

    Article  PubMed  CAS  Google Scholar 

  60. Vanhoutvin SALW, Troost FJ, Kilkens TOC, et al, 2009 The effects of butyrate enemas on visceral perception in healthy volunteers. Neurogastroenterol Motil 21: 952–e976.

    Article  PubMed  CAS  Google Scholar 

  61. Ridaura VK, Faith JJ, Rey FE, et al, 2013 Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 341: 1241214.

    Article  PubMed  CAS  Google Scholar 

  62. Hatoum IJ, Greenawalt DM, Cotsapas C, et al, 2011 Heritability of the weight loss response to gastric bypass surgery. J Clin Endocr Metab 96: 1630–1633.

    Article  CAS  Google Scholar 

  63. Jia VL, 2011 Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. Gut 60: 1214–1223.

    Article  CAS  Google Scholar 

  64. Furet JP, Kong LC, Tap J, et al, 2010 Differential Adaptation of Human Gut Microbiota to Bariatric Surgery-Induced Weight Loss: Links With Metabolic and Low-Grade Inflammation Markers. Diabetes 59: 3049–3057.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  65. Liou AP, Paziuk M, Jr., LJ, et al, 2013 Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transi Med 5: 178ra141.

    Google Scholar 

  66. Zhang L, Bahl MI, Hellgren L, et al, 2015 Obesity-associated fecal microbiota from human modulates body mass and metabolites in mice. EMBL Conference 2015, Heidelberg, Germany.

  67. U.S. Food and Drug Administration, FDA Drug Definition. FDA Glossary of Terms. Accessed December 14 2016; https://doi.org/www.fda.gov/drugs/informationon.drugs/ucm079436.htm#D.

  68. FDA, 2014 Draft Guidance for Industry: Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Standard Therapies. Silver Sping, MD: US Food and Drug Administration.

    Google Scholar 

  69. Allen-Vercoe E, Reid G, Viner N, et al, 2012 A Canadian Working Group report on fecal microbial therapy: microbial ecosystems therapeutics. Can J Gastroenterol 26: 457–462.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Smith, Mark B, Kelly, et al, 2014 Policy: How to regulate faecal transplants. Nature 506: 290–291.

    Article  PubMed  Google Scholar 

  71. Van NE, Speelman P, Nieuwdorp M, et al, 2014 Fecal microbiota transplantation: facts and controversies. Curr Opin Gastroen 30: 34–39.

    Article  Google Scholar 

  72. Kang Y, Cai Y, Zhang X, et al, 2016 Altered gut microbiota in RA: implications for treatment. Z Rheumatol 76: 451–457.

    Article  CAS  Google Scholar 

  73. Kang YB, Cai Y, Zhang H, 2016 Gut microbiota and allergy/asthma: From pathogenesis to new therapeutic strategies. Allergol Immunopathol 45: 305–309.

    Article  Google Scholar 

  74. Kelly CR, Kahn S, Kashyap P, et al, 2015 Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. Gastroenterology 149: 223–237.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical faculty, Kunming University of Science and Technology, No.727 South Jingming Rd., Chenggong District, 650500, Kunming, China

    Yongbo Kang Ph.D. & Yue Cai

  2. Genetics and Pharmacogenomics Laboratory, Kunming University of Science and Technology, Kunming, Yunnan, China

    Yongbo Kang Ph.D.

  3. Pathogen biology Laboratory, Kunming University of Science and Technology, Kunming, Yunnan, China

    Yue Cai

Authors
  1. Yongbo Kang Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yue Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yongbo Kang Ph.D..

Additional information

Equal contributors

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kang, Y., Cai, Y. Gut microbiota and obesity: implications for fecal microbiota transplantation therapy. Hormones 16, 223–234 (2017). https://doi.org/10.1007/BF03401517

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03401517

Key words

Search

Navigation